Abstract
New series of 3-(substituted-2-chloroquinolin-3-yl)-1-(4-(1H-pyrrol-1-yl)phenyl)prop-2-en-1-ones 4(a-e)/3-(substituted-2-methoxyquinolin-3-yl)-1-(4-(1H-pyrrol-1-yl)phenyl)prop-2-en-1-ones 6(a-e) were synthesized by base catalyzed reaction/chalcone synthesis. The synthesis of 3-(substituted-2-chloroquinolin-3-yl)-1-(4-(1H-pyrrol-1-yl)phenyl)prop-2-en-1-ones 4(a-e) was achieved by cold stirring of substituted-2-chloroquinoline-3-carbaldehydes 2(a-e) with 1-(4-(1H-pyrrol-1-yl)phenyl)ethan-1-one (3) in ethanol in the presence of sodium hydroxide. Further, synthesis of 3-(substituted-2-methoxyquinolin-3-yl)-1-(4-(1H-pyrrol-1-yl)phenyl)-prop-2-en-1-ones 6(a-e) was achieved by cold stirring of substituted-2-methoxyquinoline-3-carbaldehydes 5(a-e) with 1-(4-(1H-pyrrol-1-yl)phenyl)ethan-1-one (3) in the presence of ethanol and sodium hydroxide. In vitro anti-mycobacterial study of newly synthesized molecules against Mycobacterium tuberculosis H(37)Rv strain has shown substantial minimum inhibitory concentration values, also all the synthesized molecules correspondingly tested for in vitro antibacterial activity and molecules disclosed good inhibition values against Staphylococcus aureus (Gram-positive) than Escherichia coli (Gram-negative).